MedTrace Logo

Preventing Cognitive Decline with Metformin

NCT04511416 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2024-10-02

No results posted yet for this study

Summary

A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.

Conditions

Interventions

DRUG

Metformin XR, 500-2000mg nocte

Metformin XR, 500-2000mg nocte

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Garvan Institute of Medical Research

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04511416 on ClinicalTrials.gov